Situation normale

NUCLEIS
 SA

4000 Liège
Since 09/06/2017
BE0676683084
Financial Health Indicator
3
Equity
€-882.8K
-79% YoY
Gross Operating Margin
€858.9K
+13% YoY
EBITDA
€-589.7K
-21% YoY
Gain/Loss
€-967.0K
-16% YoY
Employees
13
+1% YoY

Detailed insights into NUCLEIS’s financial history

See financial trends including, equity, operating income, profit/loss and employees of NUCLEIS. Compare KPI’s against similar companies. Explore financial ratios, annual accounts and much more.

Financials 1
Financials 2
Financials 3
Financials 4
2023 2022 2021 2020
Equity
-882.8K
-4.1M
-3.1M
-1.6M
Gross Operating Margin
858.9K
761.2K
204.6K
-179.0K
Gain/Loss
-967.0K
-1.1M
-1.6M
-1.7M
Employees
13.9
13.8
13
13

Find similar companies like NUCLEIS

Find more companies with similar activities to NUCLEIS from our extensive database.

Frequently asked questions about NUCLEIS

  • What is NUCLEIS’s official website?

    NUCLEIS’s official website is https://nucleis.eu.

  • What is the email adress of NUCLEIS?

    You can contact NUCLEIS at the email address info@nucleis.eu.

  • Where is NUCLEIS located?

    NUCLEIS’s headquarters is located in Allée du Six-Août 8 , 4000 Liège.

  • What are the primary activities of NUCLEIS?

    NUCLEIS’s primary activities include: radiopharmacie, médicaments.

  • When was NUCLEIS founded?

    NUCLEIS was founded in 2017-06-09. NUCLEIS has been active for 8 years.

  • What are NUCLEIS’s NACEBEL codes?

    NUCLEIS’s NACEBEL codes are
    • 21209 Fabrication d'autres produits pharmaceutiques (2008)
    • 21100 Fabrication de produits pharmaceutiques de base (2008)
    • 72110 Recherche-développement en biotechnologie (2008)

  • What is NUCLEIS’s VAT number?

    NUCLEIS’s VAT number is BE0676683084.

  • What is NUCLEIS’s juridical form?

    NUCLEIS’s juridical type is Société anonyme (SA).

  • How many employees does NUCLEIS have?

    NUCLEIS has 13 employees.

  • How is the financial situation of NUCLEIS?

    openthebox has estimated that NUCLEIS’s financial health score to be 3/10.